Biomea Fusion Inc. has prepared new fused pyrimidine compounds acting as menin (MEN1)/KMT2A (MLL) interaction inhibitors. They are reported to be potentially useful for the treatment of cancer, osteoporosis, autoimmune diseases, inflammatory diseases, type 1 and 2 diabetes.
Prostatic-specific antigen (PSA) is commonly used as a screening tool for prostate cancer but presents limited sensitivity and specificity. Therefore, research efforts are focused on searching for novel noninvasive diagnostic biomarkers.
c-Jun N-terminal kinases (JNKs) have been proposed as therapeutic targets in multiple pathologies, including cancer, inflammation and neuronal and metabolic diseases. SP-600125 is one of the first-generation reversible ATP-competitive inhibitors of JNK1/2/3 and has shown anticancer potential against leukemia, lung adenocarcinoma and pancreatic cancer, among others.
Hoth Therapeutics Inc. has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA), providing Hoth with exclusive rights to a jointly owned patent portfolio co-developed by the VA and Emory University.
The protease mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) is a signaling protein with both molecular scaffolding and protease activity involved in lymphocyte activation. MALT1 is considered a therapeutic target for chronic lymphocytic leukemia (CLL) in patients who develop resistance to Bruton tyrosine kinase (BTK) inhibitors.
Hangzhou Sino-US Huadong Medicine Co. Ltd. and Synerk Pharmatech (Suzhou) Co. Ltd. have entered into a strategic collaboration in which the two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726.
Due to its dual role in adaptive immune responses, modulation of endoplasmic reticulum aminopeptidase 1 (ERAP1) is considered a potential strategy to both boost cancer immunotherapies or reduce self-antigen generation in the context of autoimmune diseases.
Among the most profound results presented at the 2024 European Society for Medical Oncology (ESMO) Congress were the 10-year data from the Checkmate-067 and Keynote-006 trials of Opdivo and Keytruda as first-line agents in advanced or metastatic melanoma in which 10-year overall survival topped 40%. The success of checkpoint blockade, however, has not extended to all tumor types, but in 2024, molecular studies have led to advances in gene therapies and a multitude of approaches that have opened the door to hope.
Casma Therapeutics Inc. has described autophagy targeting chimeras (AUTACs) comprising sequestosome-1 (ubiquitin-binding protein p62; SQSTM1) ligands coupled to an echinoderm microtubule-associated protein-like 4-ALK (EML4- ALK)-targeting moiety via a linker.
Centennial Therapeutics LLC has divulged ketohexokinase (KHK) inhibitors reported to be useful for the treatment of nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
RSS
